Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Shares Outstanding (Weighted Average) (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 2.59% to $14.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.3 million, a 2.59% decrease, with the full-year FY2025 number at $14.3 million, down 2.59% from a year prior.
  • Shares Outstanding (Weighted Average) was $14.3 million for Q4 2025 at Anika Therapeutics, down from $14.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $14.8 million in Q2 2024 to a low of $14.3 million in Q1 2025.
  • A 4-year average of $14.6 million and a median of $14.7 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): rose 1.29% in 2023, then fell 2.73% in 2025.
  • Anika Therapeutics' Shares Outstanding (Weighted Average) stood at $14.5 million in 2022, then grew by 0.78% to $14.7 million in 2023, then increased by 0.44% to $14.7 million in 2024, then dropped by 2.59% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Shares Outstanding (Weighted Average) are $14.3 million (Q4 2025), $14.4 million (Q3 2025), and $14.3 million (Q1 2025).